Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KRAS mutation + STK11 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

STK11 deletion + KRAS mutation (6)

KRAS G12C + PD-L1 overexpression (4)

KRAS mutation + PD-L1 expression (4)

CPS1 overexpression + KRAS mutation + STK11 mutation (3)

HER-2 amplification + KRAS G12D (3)

KEAP1 deletion + KRAS mutation (3)

PD-L1 overexpression + KRAS mutation (3)

EGFR exon 19 deletion + KRAS mutation (2)

KRAS G12C + PD-L1 underexpression (2)

KRAS mutation + PD-L1 negative (2)

MSI-L/dMMR + KRAS G12V (2)

STK11 mutation + TMB-H (2)

AXL overexpression + KRAS G12C (1)

CDH2 overexpression + KRAS wild-type (1)

Chr t(11;14) + KRAS mutation (1)

EGFR C797S + KRAS amplification + RB1 deletion (1)

EGFR L858R + KRAS amplification + RB1 deletion (1)

EGFR T790M + KRAS amplification + RB1 deletion (1)

EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)

EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)

EGFR expression + KRAS G12C (1)

EGFR overexpression + KRAS 13D (1)

EGFR overexpression + KRAS mutation (1)

FGFR1 overexpression + KRAS G12C (1)

GNA13 deletion + KRAS mutation (1)

GOPC-ROS1 fusion + KRAS Q61H (1)

HER-2 amplification + KRAS exon 2 wild-type (1)

HER-2 amplification + KRAS wild-type (1)

HER-2 overexpression + KRAS wild-type (1)

IGF1R overexpression + KRAS mutation (1)

IR overexpression + KRAS mutation (1)

IRS2 amplification + KRAS mutation (1)

KEAP1 mutation + KRAS wild-type (1)

KRAS A146 + TMB-H (1)

KRAS G12C + PD-L1 expression (1)

KRAS G12C + PD-L1 underexpression + STK11 mutation (1)

KRAS G12D + Chr del(9)(p21) (1)

KRAS G12D + HER-2 amplification + TMB-H (1)

KRAS G12D + TP53 deletion (1)

KRAS amplification + BRAF wild-type (1)

KRAS amplification + RAS wild-type (1)

KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)

KRAS mutation + BCL2A1 overexpression (1)

KRAS mutation + CDK9 overexpression + HR positive (1)

KRAS mutation + EGFR amplification (1)

KRAS mutation + ER expression (1)

KRAS mutation + HER-2 positive (1)

KRAS mutation + HR positive (1)

KRAS mutation + PD-L1 underexpression (1)

KRAS mutation + PIK3CA wild-type (1)

KRAS mutation + PTPN11 overexpression (1)

KRAS mutation + TP53 mutation + GNA13 deletion (1)

KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)

KRAS mutation + YKL-40 overexpression (1)

KRAS wild-type + BRAF V600E (1)

KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)

KRAS mutation + STK11 mutation + AXL expression (1)

MLL-AFF1 fusion + KRAS mutation (1)

MSI-H/dMMR + KRAS G12D (1)

MSI-H/dMMR + KRAS Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

MTAP deletion + KRAS G12C (1)

PD-L1 negative + KRAS G12C (1)

PD-L1 overexpression + KRAS G12C + TP53 mutation (1)

POMK-NRG1 fusion + KRAS mutation (1)

POMK‐NRG1 fusion + KRAS G12D (1)

PTEN deletion + KRAS G12C (1)

RET positive + KRAS G12V (1)

ROS1 fusion + KRAS G12C (1)

STK11 mutation + KRAS mutation + TP53 deletion (1)

STRN-ALK fusion + KRAS G13D (1)

TP53 S12F + KRAS G12D + TMB-L (1)

PD-L1 deletion + STK11 mutation (1)

PD-L1 expression + STK11 mutation (1)

PD-L1 expression + STK11 mutation + JAK2 mutation (1)

STK11 deletion + TMB-H (1)

STK11 deletion + TTF1 positive (1)

STK11 mutation + TMB-H + PD-L1 overexpression (1)

HER-2 amplification + KRAS G12C (0)

PRMT5 overexpression + KRAS mutation (0)

STK11 deletion + KRAS mutation (6)

KRAS G12C + PD-L1 overexpression (4)

KRAS mutation + PD-L1 expression (4)

CPS1 overexpression + KRAS mutation + STK11 mutation (3)

HER-2 amplification + KRAS G12D (3)

KEAP1 deletion + KRAS mutation (3)

PD-L1 overexpression + KRAS mutation (3)

EGFR exon 19 deletion + KRAS mutation (2)

KRAS G12C + PD-L1 underexpression (2)

KRAS mutation + PD-L1 negative (2)

MSI-L/dMMR + KRAS G12V (2)

STK11 mutation + TMB-H (2)

AXL overexpression + KRAS G12C (1)

CDH2 overexpression + KRAS wild-type (1)

Chr t(11;14) + KRAS mutation (1)

EGFR C797S + KRAS amplification + RB1 deletion (1)

EGFR L858R + KRAS amplification + RB1 deletion (1)

EGFR T790M + KRAS amplification + RB1 deletion (1)

EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)

EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)

EGFR expression + KRAS G12C (1)

EGFR overexpression + KRAS 13D (1)

EGFR overexpression + KRAS mutation (1)

FGFR1 overexpression + KRAS G12C (1)

GNA13 deletion + KRAS mutation (1)

GOPC-ROS1 fusion + KRAS Q61H (1)

HER-2 amplification + KRAS exon 2 wild-type (1)

HER-2 amplification + KRAS wild-type (1)

HER-2 overexpression + KRAS wild-type (1)

IGF1R overexpression + KRAS mutation (1)

IR overexpression + KRAS mutation (1)

IRS2 amplification + KRAS mutation (1)

KEAP1 mutation + KRAS wild-type (1)

KRAS A146 + TMB-H (1)

KRAS G12C + PD-L1 expression (1)

KRAS G12C + PD-L1 underexpression + STK11 mutation (1)

KRAS G12D + Chr del(9)(p21) (1)

KRAS G12D + HER-2 amplification + TMB-H (1)

KRAS G12D + TP53 deletion (1)

KRAS amplification + BRAF wild-type (1)

KRAS amplification + RAS wild-type (1)

KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)

KRAS mutation + BCL2A1 overexpression (1)

KRAS mutation + CDK9 overexpression + HR positive (1)

KRAS mutation + EGFR amplification (1)

KRAS mutation + ER expression (1)

KRAS mutation + HER-2 positive (1)

KRAS mutation + HR positive (1)

KRAS mutation + PD-L1 underexpression (1)

KRAS mutation + PIK3CA wild-type (1)

KRAS mutation + PTPN11 overexpression (1)

KRAS mutation + TP53 mutation + GNA13 deletion (1)

KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)

KRAS mutation + YKL-40 overexpression (1)

KRAS wild-type + BRAF V600E (1)

KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)

KRAS mutation + STK11 mutation + AXL expression (1)

MLL-AFF1 fusion + KRAS mutation (1)

MSI-H/dMMR + KRAS G12D (1)

MSI-H/dMMR + KRAS Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

MTAP deletion + KRAS G12C (1)

PD-L1 negative + KRAS G12C (1)

PD-L1 overexpression + KRAS G12C + TP53 mutation (1)

POMK-NRG1 fusion + KRAS mutation (1)

POMK‐NRG1 fusion + KRAS G12D (1)

PTEN deletion + KRAS G12C (1)

RET positive + KRAS G12V (1)

ROS1 fusion + KRAS G12C (1)

STK11 mutation + KRAS mutation + TP53 deletion (1)

STRN-ALK fusion + KRAS G13D (1)

TP53 S12F + KRAS G12D + TMB-L (1)

PD-L1 deletion + STK11 mutation (1)

PD-L1 expression + STK11 mutation (1)

PD-L1 expression + STK11 mutation + JAK2 mutation (1)

STK11 deletion + TMB-H (1)

STK11 deletion + TTF1 positive (1)

STK11 mutation + TMB-H + PD-L1 overexpression (1)

HER-2 amplification + KRAS G12C (0)

PRMT5 overexpression + KRAS mutation (0)

›

KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KRAS mutation + STK11 mutation	Lung Adenocarcinoma	KRAS mutation + STK11 mutation	Lung Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D
KRAS mutation + STK11 mutation	Lung Adenocarcinoma	KRAS mutation + STK11 mutation	Lung Adenocarcinoma	pembrolizumab + BGB324 Sensitive: D – Preclinical pembrolizumab + BGB324 Sensitive : D	pembrolizumab + BGB324 Sensitive: D – Preclinical pembrolizumab + BGB324 Sensitive : D